Get it on Google Play

Entrada Therapeutics reports early DMD drug trial safety data

October 14, 2026 7:00 AM EDT Send to a Friend
Entrada Therapeutics (Nasdaq: TRDA) announced topline results from the first cohort of its Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login